GeoWealth Management LLC Has $728,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

GeoWealth Management LLC boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 165.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,366 shares of the medical device company's stock after purchasing an additional 5,836 shares during the period. GeoWealth Management LLC's holdings in DexCom were worth $728,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Watts Gwilliam & Co. LLC acquired a new stake in DexCom in the 4th quarter valued at about $3,334,000. Congress Asset Management Co. increased its holdings in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC raised its position in DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after purchasing an additional 222,548 shares during the last quarter. First Hawaiian Bank lifted its holdings in DexCom by 556.1% during the 4th quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after buying an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth $5,812,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 1.2 %

NASDAQ DXCM traded up $0.88 on Friday, reaching $71.66. The company had a trading volume of 2,857,981 shares, compared to its average volume of 4,237,081. The company's fifty day moving average is $73.09 and its 200-day moving average is $76.63. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $138.81. The firm has a market capitalization of $28.10 billion, a price-to-earnings ratio of 50.11, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last 90 days. 0.32% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on DXCM shares. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Mizuho assumed coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.